In fact, among 130 experimental and clinical drugs, MYCN-amplified cell lines (20/26 of which were neuroblastoma cell lines) showed the most significant shift in half maximal inhibitory concentration (IC50) toward sensitivity with ABT-263 than any other drug compared with MYCN-WT cell lines (Table S1, top 39 by IC50 shift listed). This evidence concerns the gene MYCN and neuroblastoma.